Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof
The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.
1. An anti-PD-L1/anti-4-1BB bispecific antibody, comprising an anti-PD-L1 antibody or an antigen-binding fragment thereof and an anti-4-1BB antibody or an antigen-binding fragment thereof, wherein
the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 1; a VH CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 2 and 3; a VH CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 4, 5, 262, 263, 264, 265, 266 and 267; a VL CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 6, 268 and 269; a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 7; and a VL CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 8, 270, 271 and 272; and
the anti-4-1BB antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 10 and 11; a VH CDR2 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 12 and 13; a VH CDR3 comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 14, 15, 16 and 17; a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 18; a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 19; and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 20.
2. The anti-PD-L1/anti-4-1BB bispecific antibody of claim 1 , wherein the anti-PD-L1 antibody or antigen-binding fragment thereof is capable of specifically binding to an immunoglobulin C (Ig C) domain of a human Programmed death-ligand 1 (PD-L1) protein, wherein the Ig C domain consists of amino acid residues 133-225.
3. The anti-PD-L1/anti-4-1BB bispecific antibody of claim 1 , wherein the anti-PD-L1 antibody or antigen-binding fragment thereof does not bind to an immunoglobulin V (Ig V) domain of the PD-L1 protein, wherein the Ig V domain consists of amino acid residues 19-127.
4. The anti-PD-L1/anti-4-1BB bispecific antibody of claim 1 , wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 103, and 104, or a polypeptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 103, and 104.
5. The anti-PD-L1/anti-4-1BB bispecific antibody of claim 1 , wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 105, and 106, or a peptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 105, and 106.
6. The anti-PD-L1/anti-4-1BB bispecific antibody of claim 1 , wherein the anti-4-1BB antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 21, 22, 23, and 24, or a polypeptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 21, 22, 23, and 24.
7. The anti-PD-L1/anti-4-1BB bispecific antibody of claim 1 , wherein the anti-4-1BB antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 25 and 26, or a peptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 25 and 26.
8. The anti-PD-L1/anti-4-1BB bispecific antibody of claim 1 , which is in the form of IgG-scFv form.
9. A method for treating a disease associated with PD-L1, 4-1BB, or both thereof, comprising administering to the patient a composition comprising the anti-PD-L1/anti-4-1BB bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.
10. The method of claim 9 , wherein the disease associated with PD-L1, 4-1BB, or both thereof is cancer.